BR112017001403A2 - métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto - Google Patents

métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto

Info

Publication number
BR112017001403A2
BR112017001403A2 BR112017001403A BR112017001403A BR112017001403A2 BR 112017001403 A2 BR112017001403 A2 BR 112017001403A2 BR 112017001403 A BR112017001403 A BR 112017001403A BR 112017001403 A BR112017001403 A BR 112017001403A BR 112017001403 A2 BR112017001403 A2 BR 112017001403A2
Authority
BR
Brazil
Prior art keywords
conjugating
agent
protein containing
thiol moiety
methods
Prior art date
Application number
BR112017001403A
Other languages
English (en)
Portuguese (pt)
Inventor
Tucker Bechtel Charity
Franklin Jayme
GORRELL Jeffrey
Hutchinson Matthew
Tully Timothy
Xin LIN Xin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112017001403A2 publication Critical patent/BR112017001403A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112017001403A 2014-07-24 2015-07-17 métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto BR112017001403A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028679P 2014-07-24 2014-07-24
PCT/US2015/040931 WO2016014360A1 (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Publications (1)

Publication Number Publication Date
BR112017001403A2 true BR112017001403A2 (pt) 2017-11-21

Family

ID=55163580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001403A BR112017001403A2 (pt) 2014-07-24 2015-07-17 métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto

Country Status (15)

Country Link
US (2) US11370838B2 (https=)
EP (1) EP3172219A4 (https=)
JP (3) JP6956630B2 (https=)
KR (1) KR102463267B1 (https=)
CN (1) CN106536540A (https=)
AR (1) AR101304A1 (https=)
AU (2) AU2015294389B2 (https=)
BR (1) BR112017001403A2 (https=)
CA (1) CA2955007C (https=)
IL (1) IL250148B2 (https=)
MX (2) MX2017001022A (https=)
MY (1) MY198629A (https=)
RU (2) RU2021106673A (https=)
SG (2) SG11201700365TA (https=)
WO (1) WO2016014360A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536540A (zh) * 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
JP7148524B2 (ja) 2017-02-08 2022-10-05 ファイザー・インク キャップされたおよびキャップされていない抗体システインのための大規模産生プロセス、ならびに治療的タンパク質コンジュゲーションにおけるその使用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2665353B2 (ja) * 1988-09-10 1997-10-22 住商ファーマインターナショナル株式会社 双特異性抗体の製造法
JPH0278699A (ja) 1988-09-12 1990-03-19 Green Cross Corp:The ベンゾイルウレア系化合物・アルブミン複合体
JPH02218700A (ja) * 1989-02-17 1990-08-31 Nippon Kayaku Co Ltd 双特異性抗体及びそれを用いる養子免疫療法
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ZA955789B (en) 1994-07-15 1996-03-11 Novo Nordisk As A method of converting a hydrophobic derivative of a polypeptide into the native form
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11124395A (ja) 1997-10-16 1999-05-11 Seiwa Kasei Kk システイン導入ペプチドおよびその製造方法
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
CA2374050A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
WO2002062827A2 (en) 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
AU2004213053C1 (en) * 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
AU2005218642B2 (en) * 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
JP4865728B2 (ja) * 2004-12-29 2012-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ポリペプチドの三硫化物誘導体の形成を防止する方法
ES2567402T3 (es) * 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
JP5394246B2 (ja) 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
EP2144628B1 (en) * 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
MX2010008310A (es) * 2008-01-31 2010-12-21 Georgia Pacific Chemicals Llc Composicion oxidada y maleatada modificada.
DK2483289T4 (da) * 2009-10-02 2025-05-19 Biogen Ma Inc Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
EP2542576B1 (en) * 2010-03-02 2016-04-20 Seattle Genetics, Inc. Methods for screening antibodies
JP2014500248A (ja) * 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
DK2707383T3 (en) * 2011-05-13 2018-07-23 Biogen Ma Inc PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
JP2015502397A (ja) * 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
AU2013256596A1 (en) * 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
MX2014015682A (es) * 2012-06-19 2015-07-23 Polytherics Ltd Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos.
CN106536540A (zh) * 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法

Also Published As

Publication number Publication date
AU2015294389B2 (en) 2021-04-29
SG10202102467RA (en) 2021-04-29
JP7219256B2 (ja) 2023-02-07
JP6956630B2 (ja) 2021-11-02
JP2021046419A (ja) 2021-03-25
AU2021209196B2 (en) 2023-02-02
CA2955007C (en) 2023-04-11
MX2022012589A (es) 2022-11-09
US20220372141A1 (en) 2022-11-24
AR101304A1 (es) 2016-12-07
IL250148A0 (en) 2017-03-30
WO2016014360A1 (en) 2016-01-28
US11370838B2 (en) 2022-06-28
MY198629A (en) 2023-09-11
RU2017105428A (ru) 2018-08-29
KR102463267B1 (ko) 2022-11-03
CN106536540A (zh) 2017-03-22
AU2021209196A1 (en) 2021-08-19
KR20170028435A (ko) 2017-03-13
SG11201700365TA (en) 2017-02-27
AU2015294389A1 (en) 2017-02-23
IL250148B (en) 2022-11-01
JP2023052645A (ja) 2023-04-11
RU2017105428A3 (https=) 2018-08-29
MX2017001022A (es) 2017-12-20
EP3172219A4 (en) 2018-04-04
JP2017526652A (ja) 2017-09-14
IL250148B2 (en) 2023-03-01
US20170209593A1 (en) 2017-07-27
RU2744978C2 (ru) 2021-03-17
EP3172219A1 (en) 2017-05-31
CA2955007A1 (en) 2016-01-28
RU2021106673A (ru) 2021-11-25

Similar Documents

Publication Publication Date Title
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
CO2017010618A2 (es) Anticuerpos contra icos
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
CU20150128A7 (es) Conjugados fármaco-anticuerpo
UY35399A (es) Conjugados de fármacos con anticuerpos
UY36075A (es) Derivados de tubulisina
BR112016012666A2 (pt) conjugado, anticorpos, formulação farmacêutica e usos de conjugado
BR112017006602A2 (pt) método de conjugação de um polipeptídeo
BR112017013006A2 (pt) método para vedação de tubulação usando um pig de gel
BR112017012042A2 (pt) composição de conjugado anticorpo-droga e método para tratar câncer de mama
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
MX2019004434A (es) Anticuerpos anti-edb y conjugados anticuerpo-fármaco.
MX373017B (es) Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
BR112017004246A2 (pt) mancal simples ou parte do mesmo, método para a sua produção e uso de uma liga de cucrzr como um material de mancal simples
CU24453B1 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112018012524A2 (pt) anticorpos variantes para conjugação sítio-específica
BR112017001403A2 (pt) métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto
BR102015024914B8 (pt) Artigo absorvente que demonstra deformação controlada e distribuição longitudinal de fluidos
BR122020011353A8 (pt) Artigo absorvente
PT3144676T (pt) Kit compreendendo anticorpo que se liga especificamente à proteína de fator b do complemento e anticorpo que se liga especificamente à proteína do antigénio carboidrato 19-9 para diagnosticar o cancro pancreático
BR112017013032A2 (pt) método para vedação de tubulação usando um pig de gel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.